Latest Cardiovascular Ai News

Page 1 of 1
Echo IQ’s FDA-cleared EchoSolv AS platform processed 9,697 full-result assessments in the September quarter, while the company ended the period with A$107.8 million in cash. The stronger balance sheet gives it room to pursue US enterprise deployments, but commercial conversion and the unresolved EchoSolv HF regulatory pathway remain the key tests.
Victor Sage
Victor Sage
26 Oct 2026
Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.
Ada Torres
Ada Torres
27 July 2026
Echo IQ has locked in a pivotal exclusive data licensing deal with Advara HeartCare, gaining access to as many as one million de-identified echocardiography studies, a move set to turbocharge its cardiovascular AI development.
Ada Torres
Ada Torres
2 July 2026
Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.
Ada Torres
Ada Torres
1 July 2026
Pro Medicus has inked a binding Heads of Agreement with Echo IQ to finance and resell AI algorithms targeting cardiovascular conditions, aiming to integrate these into its Visage 7 Cardiology platform.
Ada Torres
Ada Torres
25 June 2026

Browse the archive

Full archive